Immix Biopharma Raises $100M in Financing Round
ByAinvest
Monday, Dec 8, 2025 7:55 am ET1min read
IMMX--
Immix Biopharma has priced a $100 million offering. The clinical-stage biopharmaceutical company is focused on CAR-T therapy for AL Amyloidosis, autoimmune disease, and multiple myeloma. Its lead asset, CAR-T NXC-201, is being evaluated in a Phase Ib/IIa clinical trial. The company is also developing tissue-specific therapeutic IMX-110 for advanced solid tumors.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet